Macrophage-specific Msr1-deficient mice are resistant to diet-induced metabolic disorders, as evidenced by fewer hepatic foamy macrophages, reduced inflammation, improved glucose tolerance and hepatic lipid metabolism [61], suggesting that blocking MSR1 signaling could be a promising approach for the treatment of MASLD. This evidence concerns the gene MSR1 and metabolic dysfunction-associated steatotic liver disease.